Drugs in Dev. Infections and Infectious Diseases
Phase I/ Phase II
India 
Lead Product(s) : AKS-452
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKS-452 is a CoV-2 protein subunit vaccine based on the Ambifect™ Fc-fusion protein platform. It induces a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel coronavirus spike protein.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 24, 2022
Lead Product(s) : AKS-452
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DFA-02
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Duke Clinical Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
DFA-02 in Patients Undergoing Colorectal Surgery
Details : DFA-02 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Surgical Wound Infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2011
Lead Product(s) : DFA-02
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Duke Clinical Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetravalent Chimeric Dengue Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DengiAll, a single-dose live-attenuated tetravalent vaccine induced robust, balanced neutralizing antibody responses against all four Dengue virus serotypes. After single-dose, more than 80% of participants showed Tri-valent response and ~95% showed mult...
Product Name : DengiAll
Product Type : Vaccine
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Tetravalent Chimeric Dengue Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Derived from Mesenchymal stem cells obtained from donated umbilical cord tissue, Mesocel is set to treat patients suffering from life-threatening Covid-19 pneumonia and acute respiratory distress.
Product Name : Mesocel
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 15, 2021
Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : HDT Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India
Details : Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : HDT Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HGCO19 Vaccine Candidate: Gennova Starts Enrolment for Phase 1/2 Human Clinical Trials
Details : HCCOG19 is an indigenously developed vaccine on a mRNA platform. Gennova has initiated the enrolment of volunteers for Phase 1/2 clinical trials for its mRNA vaccine candidate HGCO19, the Department of Biotechnology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 13, 2021
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicord
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
Details : Epicord is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 08, 2021
Lead Product(s) : Epicord
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $5.0 million
Deal Type : Funding
CEPI Partners with Biological E To Advance Development and Manufacture of Covid-19 Vaccine Candidate
Details : CEPI will initially contribute up to $5m toward the cost of scaling up the process for manufacturing the COVAX, and will explore providing additional funding to Bio E with the goal of potentially enabling the production of 100 million doses in 2021.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 29, 2020
Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $5.0 million
Deal Type : Funding
Lead Product(s) : ZyCoV-D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Cadila Seeks Govt Nod to Start Phase-III Clinical Trials of Covid-19 Vaccine ZyCoVD
Details : Zydus Cadila's ZyCoV-D', has been found to be safe and immunogenic in the Phase I/II clinical trials, and the company is seeking regulatory approval to commence Phase-III trials.
Product Name : ZyCoV-D
Product Type : Vaccine
Upfront Cash : Inapplicable
December 24, 2020
Lead Product(s) : ZyCoV-D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Bayer college of medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
India's Biological E. to Start Vaccine Late-Stage Trials in April
Details : Company said in November it had started early-stage and mid-stage human trials of its vaccine candidate, being developed in collaboration with Baylor College of Medicine in Houston and U.S.-based Dynavax Technologies Corp, and expects results by February...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 18, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Bayer college of medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
